Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Phase 2 Recruiting 45 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Renmin Hospital of Wuhan University · collab

NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.

Timeline

Start: 2023-12-01
Primary completion: 2024-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	1200 mg	Intravenous
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Fruquintinib	Small molecule	3 mg	Oral
Subject	Fruquintinib	Small molecule	4 mg	Oral
Subject	Oxaliplatin	Small molecule	130 mg/m2	—

Indications

No indication recorded.